PEGylated substance P augments therapeutic angiogenesis in diabetic critical limb ischemia

다국어 초록 (Multilingual Abstract)

Substance P (SP) is a therapeutic peptide that has been widely used to induce angiogenesis and tissue regeneration. However, its therapeutic efficacy is often limited due to rapid degradation in vivo and a short half-life (˜1 min) after systemic administration. In the present study, we chemically modified SP with polyethylene glycol (PEG) to generate long-lasting formulations with increased stability and extended retention time in vivo and evaluated their ability to enhance therapeutic angiogenesis. Compared to the unmodified SP, PEGylated SP (PEG-SP) exhibited significantly increased half-life in vivo (˜360-fold increase in normal mouse and ˜120-fold increase in diabetic mouse). Systemic injection of PEG-SP led to a marked increase in therapeutic efficacy and angiogenesis in diabetic hindlimb ischemia, as evident from the remarkable improvement in salvage of ischemic limb and recovery of blood perfusion in diabetic mice with limb ischemia. These formulations increased endogenous stem cell mobilization to the injured site and modulated the immune system to increase microvessel formation and reduce systemic inflammation. Importantly, PEGylation efficiently reduced the injection doses of SP while still maintaining its therapeutic efficacy. To conclude, our study demonstrated that PEG-SP formulations exhibited an improved in vivo pharmacokinetic profile with enhanced efficacy and clinically acceptable treatment regimens, thus acting as a potent therapeutic for diabetic ischemia and inflammation.

참고문헌 (Reference)

1 H. S. Hong, 15 (15): 425-, 2009

2 Y. Liu, 31 (31): 5246-, 2010

3 M. H. Jiang, 24 (24): 846-, 2013

4 H. S. Hong, 23 (23): 268-, 2015

5 S. J. Kim, 74 : 119-, 2016

6 I. Bot, 106 (106): 89-, 2010

7 G. Andersson, 45 (45): 1017-, 2011

8 W. G. La, 9 : 107-, 2014

9 A. Mashaghi, 73 (73): 4249-, 2016

10 J. E. Lim, 7 (7): 9417-, 2017

11 R. A. Skidgel, 5 (5): 769-, 1984

12 J. J. Bowden, 91 (91): 8964-, 1994

13 H. J. Park, 161 : 69-, 2018

14 Q. Wang, 32 (32): 491-, 2009

15 H. L. Levy, 124 (124): 223-, 2018

16 K. L. Furber, 7 : 47-, 2017

17 B. A. Konkle, 126 (126): 1078-, 2015

18 M. J. Roberts, 54 (54): 459-, 2002

19 C. S. Fishburn, 97 (97): 4167-, 2008

20 L. Valentin-Hansen, 289 (289): 18045-, 2014

21 M. S. Steinhoff, 94 (94): 265-, 2014

22 I. K. Ko, 26 (26): 158-, 2012

23 H. Liu, 176 (176): 2864-, 2006

24 P. Muangman, 19 (19): 508-, 2003

25 O. Z. Lerman, 162 (162): 303-, 2003

26 S. A. Eming, 6 (6): 265-, 2014

27 E. J. Bassi, 61 (61): 2534-, 2012

28 E. Tolosano, 100 (100): 4201-, 2002

29 J.G. Kiang, 2014 : 481392-, 2014

30 A. Sica, 122 (122): 787-, 2012

31 S. Kim, 225 : 98-, 2019

32 N. S. Gibran, 108 (108): 122-, 2002

33 M. A. Antezana, 119 (119): 1400-, 2002

34 D. G. Armstrong, 21 (21): 855-, 1998

35 O. M. Tepper, 106 (106): 2781-, 2002

36 R. Tamarat, 164 (164): 457-, 2004

37 F. Ferraro, 3 (3): 2011

38 R. C. Rennert, 5 (5): 79-, 2014

39 J. H. Park, 24 (24): 337-, 2016

40 D.D. Jensen, 9 (9): eaal3447-, 2017

41 V. Schellenberger, 27 (27): 1186-, 2009

42 N. Nischan, 52 (52): 11920-, 2013

43 J. M. Harris, 2 (2): 214-, 2003

44 R. Visentin, 15 (15): 1046-, 2004

45 J. M. Harris, 40 (40): 539-, 2001

46 K. V. Savoca, 578 (578): 47-, 1979

47 M. S. Hershfield, 88 (88): 7185-, 1991

48 X. W. Zhang, 10 (10): 1691-, 2014

49 M. S. Steinhoff, 94 (94): 265-, 2014

50 L. Valentin-Hansen, 289 (289): 18045-, 2014

51 P. W. Mantyh, 92 (92): 2622-, 1995

52 윤다영, "Study on chemotaxis and chemokinesis of bone marrow-derived mesenchymal stem cells in hydrogel-based 3D microfluidic devices" 한국생체재료학회 20 (20): 166-173, 2016

53 카나가벨디판쿠마, "Protein Engineering for Covalent Immobilization and Enhanced Stability through Incorporation of Multiple Noncanonical Amino Acids" 한국생물공학회 22 (22): 248-255, 2017